Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 9/20 | 0.52 |
| ▸ | PDE3B | Q13370 | 3/20 | 0.48 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.48 |
| ▸ | PDE4A | P27815 | 2/20 | 0.45 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.41 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 5/20 | 0.38 |
| ▸ | PDE9A | O76083 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20841478 | 0.80 | PDE5A (0.78) | PDE5APDE3BPDE3APDE4APDE4B | |
| SCHEMBL10201625 | 0.80 | PDE5A (0.78) | PDE5APDE3BPDE3APDE4APDE4B | |
| SCHEMBL717400 | 0.76 | PDE5A (0.60) | PDE5APDE3BPDE3APDE4APDE4B | |
| SCHEMBL7874805 | 0.74 | PDE4A (0.57) | PDE5APDE3BPDE3APDE4APDE4B | |
| SCHEMBL16503589 | 0.73 | PDE5A (0.66) | PDE5APDE3BPDE3APDE4APDE4B | |
| SCHEMBL194126 | 0.69 | PDE5A (0.59) | PDE5APDE3BPDE3APDE4APDE4B | |
| SCHEMBL232826 | 0.69 | PDE5A (0.59) | PDE5APDE3BPDE3APDE4APDE4B | |
| SCHEMBL18745385 | 0.69 | PDE4A (0.73) | PDE5APDE3BPDE4APDE4BPDE4C | |
| SCHEMBL4919006 | 0.69 | PDE4A (0.73) | PDE5APDE3BPDE4APDE4BPDE4C | |
| SCHEMBL714340 | 0.67 | PDE3B (0.69) | PDE5APDE3BPDE3APDE4APDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110312978-A1 | PDE1 INHIBITORS FOR OPHTHALMIC DISORDERS | INTRA-CELLULAR THERAPIES, INC. | 2011-12-22 | — | — | US | disclosed |
| US-20110312978-A1 | PDE1 INHIBITORS FOR OPHTHALMIC DISORDERS | INTRA-CELLULAR THERAPIES, INC. | 2011-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110312978-A1 | PDE1 INHIBITORS FOR OPHTHALMIC DISORDERS | PDE12, PDE5A, PDE3A | PDE5A 2/4885PDE3B 5/4885PDE3A 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.